AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27617380 — intervention group
Group type: COMPARATOR
Intervention: Tell-show-do method (standard of care)
Number of subjects: 14
Study 24508386 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 79
Study 24508386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 22768636 — intervention group
Group type: EXPERIMENTAL
Intervention: Handhold orientation (vertical to horizontal)
Number of subjects: 12
Study 22768636 — intervention group
Group type: EXPERIMENTAL
Intervention: Handhold diameter (large: 51 mm vs small: 22 mm to 32 mm)
Number of subjects: 12
Study 22768636 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing gloves (bare-handed vs wearing a glove on the nondominant hand)
Number of subjects: 12
Study 20031347 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP) 150 mg/day
Number of subjects: 24
Study 20031347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18661495 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (125 mg/kg/day) plus ceftazidime (100 mg/kg/day)
Number of subjects: 51
Study 18661495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (100 mg/kg/day)
Number of subjects: 51
Study 18661495 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (PIPC/TAZ + CAZ and cefozopran)
Number of subjects: 51
Study 15721732 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 6.25 to 25 mg
Number of subjects: 2061
Study 15721732 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 2061
Study 15721732 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate 25 to 50 mg
Number of subjects: 2061
Study 15721732 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 0.625 to 1.25 mg
Number of subjects: 2061
Study 15145470 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent patients
Number of subjects: 24
Study 15145470 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent patients
Number of subjects: 24
Study 10836660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (30 g) and drospirenone (3 mg)
Number of subjects: 2069
Study 10836660 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol (30 g) and desogestrel (150 g)
Number of subjects: 2069
Study 9060547 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 plus cisplatin 75 mg/m2
Number of subjects: 0
Study 9060547 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 85 mg/m2 plus cisplatin 100 mg/m2
Number of subjects: 0
Study 9060547 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A (docetaxel followed by cisplatin)
Number of subjects: 0
Study 9060547 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule B (cisplatin followed by docetaxel)
Number of subjects: 0
Study 1441860 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 60
Study 1441860 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60
Study 1441860 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (supplementary group)
Number of subjects: 60
Study 1441860 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (all patients)
Number of subjects: 60
Study 4025747 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 60
Study 4025747 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 60
Study 4025747 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study 30312416 — intervention group
Group type: EXPERIMENTAL
Intervention: Community educational workshops
Number of subjects: 0
Study 30312416 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25385527 — intervention group
Group type: EXPERIMENTAL
Intervention: Open acromioplasty (OS group)
Number of subjects: 87
Study 25385527 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty (AS group)
Number of subjects: 87
Study 25385527 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT group)
Number of subjects: 87
Study 23467655 — intervention group
Group type: EXPERIMENTAL
Intervention: Antismokeless tobacco ads
Number of subjects: 1836
Study 23467655 — intervention group
Group type: EXPERIMENTAL
Intervention: Antismokeless tobacco ads with anti-tobacco industry themes
Number of subjects: 1836
Study 23467655 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous/testimonial ads
Number of subjects: 1836
Study 23467655 — intervention group
Group type: EXPERIMENTAL
Intervention: Health effects ads
Number of subjects: 1836
Study 23467655 — intervention group
Group type: COMPARATOR
Intervention: Control ads
Number of subjects: 1836
Study 23278775 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly regimen of antitubercular drugs (2H(3)R(3)Z(3)E(3)/4H(3)R(3)) for 6 months
Number of subjects: 268
Study 20134306 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Number of subjects: 16
Study 20134306 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (triamcinolone acetonide)
Number of subjects: 16
Study 18703933 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 483
Study 18703933 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 483
Study 18703933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 15924983 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention delivered through health services
Number of subjects: 377
Study 15924983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 377
Study 12563577 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% supplemental oxygen
Number of subjects: 13
Study 12563577 — intervention group
Group type: COMPARATOR
Intervention: Room air (control group)
Number of subjects: 13
Study 10531771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg i.v.
Number of subjects: 47
Study 10531771 — intervention group
Group type: COMPARATOR
Intervention: Buscopan compositum (hyoscine butylbromide 20 mg and dipyrone 2.5 g) i.v.
Number of subjects: 47
Study 7711993 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 8
Study 7711993 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg)
Number of subjects: 8
Study 2792671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid protection (antacids, cimetidine, and sucralfate)
Number of subjects: 62
Study 2792671 — intervention group
Group type: COMPARATOR
Intervention: No acid protection
Number of subjects: 62
Study 909325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse rehabilitator intervention
Number of subjects: 102
Study 29271052 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hemostatic sealant
Number of subjects: 80
Study 29271052 — intervention group
Group type: COMPARATOR
Intervention: Bipolar coagulation
Number of subjects: 80
Study 29271052 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal (hemostatic subgroup)
Number of subjects: 80
Study 29271052 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil (hemostatic subgroup)
Number of subjects: 80
Study 26743533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional mindfulness
Number of subjects: 399
Study 24734241 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine+lornoxicam (group LL)
Number of subjects: 60
Study 24734241 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine+lornoxicam+transdermal nitroglycerine (group LL-N)
Number of subjects: 60
Study 24734241 — intervention group
Group type: COMPARATOR
Intervention: lidocaine (group L)
Number of subjects: 60
Study 22377944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG, probiotic group)
Number of subjects: 127
Study 22377944 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (placebo group)
Number of subjects: 127
Study 22377944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (probiotic and placebo)
Number of subjects: 127
Study 20803861 — intervention group
Group type: EXPERIMENTAL
Intervention: 27G Quincke needle
Number of subjects: 120
Study 20803861 — intervention group
Group type: COMPARATOR
Intervention: 27G Whitacre needle
Number of subjects: 120
Study 18322928 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraged to regulate their daily routines
Number of subjects: 71
Study 18322928 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 15715629 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-Lipuro (Braun, Melsungen, Germany)
Number of subjects: 80
Study 15715629 — intervention group
Group type: COMPARATOR
Intervention: Diprivan (AstraZeneca, Södertälie, Sweden)
Number of subjects: 80
Study 12423985 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil
Number of subjects: 393
Study 12423985 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant fluorouracil)
Number of subjects: 393
Study 10421388 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified long-chain triglycerides (6 mmol/h for 120 minutes)
Number of subjects: 6
Study 10421388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonemulsified long-chain triglycerides with addition of emulsifier
Number of subjects: 6
Study 10421388 — intervention group
Group type: COMPARATOR
Intervention: Saline with emulsifier (control)
Number of subjects: 6
Study 7593510 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-image sperm selection (CISS)
Number of subjects: 16
Study 7593510 — intervention group
Group type: COMPARATOR
Intervention: Conventional SUZI (unselected sperm)
Number of subjects: 16
Study 7593510 — intervention group
Group type: EXPERIMENTAL
Intervention: CISS
Number of subjects: 16
Study 1965077 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalized inactivated hepatitis A vaccine (180, 360, and 720 ELISA units)
Number of subjects: 3
Study 1965077 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalized inactivated hepatitis A vaccine
Number of subjects: 3
Study 382914 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.4 mg/kg) + Ketamine (2 mg/kg) + Nitrous oxide (50%)
Number of subjects: 16
Study 382914 — intervention group
Group type: COMPARATOR
Intervention: Morphine (3 mg/kg) + Nitrous oxide (50%)
Number of subjects: 16
Study 6847465 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival irrigation with saline solution
Number of subjects: 40
Study 6847465 — intervention group
Group type: COMPARATOR
Intervention: Non-irrigated eyes
Number of subjects: 40
Study 30273284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Plyometric and Change-of-Direction Training (CPT)
Number of subjects: 14
Study 30273284 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 14
Study 29352714 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent prednisone
Number of subjects: 5615
Study 29352714 — intervention group
Group type: COMPARATOR
Intervention: Control (no prednisone)
Number of subjects: 5615
Study 26544097 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC5) and external beam radiotherapy (60 Gy/30 fractions/6 weeks)
Number of subjects: 30
Study 26544097 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (paclitaxel 200 mg/m² and carboplatin AUC5) followed by external beam radiotherapy (48 Gy/20 fractions/4 weeks) with concomitant cisplatin 30 mg/m² weekly
Number of subjects: 30
Study 24449015 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vision (participants could see where they were pointing)
Number of subjects: 0
Study 24449015 — intervention group
Group type: COMPARATOR
Intervention: Blindfolded (no immediate vision)
Number of subjects: 0
Study 22695002 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive device
Number of subjects: 0
Study 22695002 — intervention group
Group type: COMPARATOR
Intervention: Convective device
Number of subjects: 0
Study 20229077 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on cervical cancer knowledge
Number of subjects: 130
Study 20229077 — intervention group
Group type: COMPARATOR
Intervention: Baseline cancer knowledge assessment
Number of subjects: 130
Study 17626040 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at a dose of 1 g twice daily
Number of subjects: 28
Study 17626040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17626040 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 28
Study 16302895 — intervention group
Group type: COMPARATOR
Intervention: PVD (group A, 92 patients)
Number of subjects: 187
Study 16302895 — intervention group
Group type: EXPERIMENTAL
Intervention: PVD combined with MIL (group B, 95 patients)
Number of subjects: 187
Study 16302895 — intervention group
Group type: COMPARATOR
Intervention: PVD (group A)
Number of subjects: 187
Study 16302895 — intervention group
Group type: EXPERIMENTAL
Intervention: PVD combined with MIL (group B)
Number of subjects: 187
Study 12066266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar paravertebral nerve block
Number of subjects: 115
Study 12066266 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 115
Study 9618125 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (6279 kJ/week of physical activity, 33,258-41,462 kJ/week diet and weekly meetings)
Number of subjects: 80
Study 9618125 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 80
Study 7653978 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 800 mg five times per day for seven days (Group A)
Number of subjects: 295
Study 7653978 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir 800 mg five times per day for seven days (Group B)
Number of subjects: 295
Study 7653978 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (both Group A and Group B)
Number of subjects: 295
Study 7653978 — intervention group
Group type: COMPARATOR
Intervention: Control group (147 patients who refused acyclovir)
Number of subjects: 295
Study 7653978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 295
Study 2696870 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl glue
Number of subjects: 43
Study 2696870 — intervention group
Group type: COMPARATOR
Intervention: Dexon subcuticular suture
Number of subjects: 43
Study 302153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at 7.5 months of age
Number of subjects: 0
Study 302153 — intervention group
Group type: COMPARATOR
Intervention: Vaccination before 7.5 months of age
Number of subjects: 0
Study 302153 — intervention group
Group type: COMPARATOR
Intervention: Maternal antibodies
Number of subjects: 0
Study 31999469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca block with 50 to 60 mL of 0.35% ropivacaine
Number of subjects: 95
Study 31999469 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of 20 mL of 0.5% ropivacaine
Number of subjects: 95
Study 31999469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca block
Number of subjects: 95
Study 30424864 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 57
Study 27689343 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenol orange juice (HPJ) (745 mg/L)
Number of subjects: 30
Study 27689343 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-polyphenol orange juice (NPJ) (299 mg/L)
Number of subjects: 30
Study 26091326 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated planning intervention (2 sessions, supportive telephone calls during 6 months)
Number of subjects: 39
Study 26091326 — intervention group
Group type: COMPARATOR
Intervention: Attention control (no specific intervention details provided)
Number of subjects: 39
Study 23324563 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 2627
Study 23324563 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccines alone
Number of subjects: 2627
Study 23324563 — intervention group
Group type: COMPARATOR
Intervention: MenC
Number of subjects: 2627
Study 21330153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored message emphasizing benefits to sexually inexperienced women
Number of subjects: 193
Study 21330153 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed message emphasizing sexual transmission of HPV
Number of subjects: 193
Study 21330153 — intervention group
Group type: COMPARATOR
Intervention: Control condition (minimal information, sexual transmission information omitted)
Number of subjects: 193
Study 18957972 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI diet
Number of subjects: 12
Study 18957972 — intervention group
Group type: COMPARATOR
Intervention: Low GI diet
Number of subjects: 12
Study 17366289 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent spirometry training
Number of subjects: 137
Study 17366289 — intervention group
Group type: COMPARATOR
Intervention: No recent spirometry training
Number of subjects: 137
Study 15461653 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 4
Study 15461653 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted plus text-based learning
Number of subjects: 4
Study 15461653 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based learning
Number of subjects: 4
Study 15461653 — intervention group
Group type: COMPARATOR
Intervention: Control (no-study) group
Number of subjects: 4
Study 15461653 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 study groups (CAI, CAI plus text, text-based)
Number of subjects: 4
Study 15461653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower achieving students using computer-based learning methods
Number of subjects: 4
Study 15461653 — intervention group
Group type: EXPERIMENTAL
Intervention: High achieving students
Number of subjects: 4
Study 10850521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg (10 mg/ml)
Number of subjects: 40
Study 10850521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg (1 mg/ml)
Number of subjects: 40
Study 10850521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg (2 mg/ml)
Number of subjects: 40
Study 10850521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 600 mg (2 mg/ml)
Number of subjects: 40
Study 10850521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 800 mg (2 mg/ml)
Number of subjects: 40
Study 10850521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (all doses)
Number of subjects: 40
Study 10850521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8834289 — intervention group
Group type: EXPERIMENTAL
Intervention: Current modes of prophylaxis and treatment for heterotopic ossification
Number of subjects: 0
Study 1435159 — intervention group
Group type: EXPERIMENTAL
Intervention: 84 rpm in a sitting position (84 Sit)
Number of subjects: 9
Study 1435159 — intervention group
Group type: COMPARATOR
Intervention: 41 rpm in a standing position (41 Stand)
Number of subjects: 9
Study 1435159 — intervention group
Group type: COMPARATOR
Intervention: 41 rpm in a sitting position (41 Sit)
Number of subjects: 9
Study 3911961 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 5 mg/kg
Number of subjects: 100
Study 3911961 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 7.5 mg/kg
Number of subjects: 100
Study 3911961 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 10 mg/kg
Number of subjects: 100
Study 3911961 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 1 mg/kg
Number of subjects: 100
Study 3911961 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen lower doses (1, 2, 3, 4 mg/kg)
Number of subjects: 100
Study 3911961 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen (all doses)
Number of subjects: 100
Study 31155997 — intervention group
Group type: EXPERIMENTAL
Intervention: motor‐cognitive dual task training (mCdtt)
Number of subjects: 60
Study 31155997 — intervention group
Group type: EXPERIMENTAL
Intervention: motor‐motor dual‐task training (mMdtt)
Number of subjects: 60
Study 31155997 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 29903391 — intervention group
Group type: EXPERIMENTAL
Intervention: App + Reminder
Number of subjects: 26
Study 29903391 — intervention group
Group type: COMPARATOR
Intervention: App
Number of subjects: 26
Study 28898136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary activity
Number of subjects: 143
Study 28898136 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 143
Study 28898136 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 143
Study 28898136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivariate regression models
Number of subjects: 143
Study 26202786 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil (Group SR, n=25)
Number of subjects: 74
Study 26202786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-dexmedetomidine (0.5 μg/kg) (Group SD5, n=24)
Number of subjects: 74
Study 26202786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-dexmedetomidine (0.7 μg/kg) (Group SD7, n=25)
Number of subjects: 74
Study 23323581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine/Mycophenolate Mofetil (CSA/MMF)
Number of subjects: 10
Study 23323581 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine/Azathioprine (CSA/AZT)
Number of subjects: 10
Study 21078194 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (17 acupuncture points used 3 times a week for 4 weeks)
Number of subjects: 150
Study 21078194 — intervention group
Group type: COMPARATOR
Intervention: Artificial tear drops (Refresh Plus®, ALLERGAN) provided for use at least once a day for 4 weeks
Number of subjects: 150
Study 18821186 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Brazilian diet
Number of subjects: 0
Study 16634340 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced therapy (mitt on the less affected hand 90% of waking hours for 12 days) with 2‐3 patients per therapist and 6 h of group training per day.
Number of subjects: 16